Journal of spine surgery (Hong Kong) · 2026
A bone graft substitute is effective for posterior spinal fusion in patients with juvenile or adolescent idiopathic scoliosis: a retrospective study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Paez Conner J, Rundell Alexandria N, Steiner Richard P, Ritzman Todd F, Floccari Lorena V
Аннотация
BACKGROUND: Bone grafting is used to achieve fusion during surgical treatment of scoliosis. While both iliac crest autografts and allografts are effective options, each has associated risks. Synthetic alternatives without added biologics may achieve fusion while reducing or avoiding many of the risks associated with other bone graft options. However, there is lack of evidence for use of synthetic bone graft products in pediatric patients. The purpose of this study is to determine the efficacy of a commercially available biphasic beta-tricalcium phosphate and hydroxyapatite synthetic bone graft substitute for posterior spinal fusion (PSF) in patients with juvenile or adolescent idiopathic scoliosis (JIS or AIS).
METHODS: We retrospectively identified patients with JIS or AIS who underwent PSF using a synthetic bone graft substitute (Mastergraft™; Medtronic, Minneapolis, MN, USA) at Akron Children's Hospital between 2015 and 2022. Patients with <23 months clinical and radiographic follow-up were excluded. Patient demographics, deformity metrics, and surgical data were collected. The primary outcome measure was fusion. Secondary outcome measures included intra-operative and post-operative complications, revision surgeries, and readmissions within 30 and 90 days.
RESULTS: A total of 179 patients were included (mean age, 14.7 years; 72.1% female). A total of 60 cc of synthetic bone graft substitute was used in the majority (91.6%) of cases. At mean 40.9 months (range, 23-98 months) follow-up, 98.9% of patients successfully achieved fusion. There were 7 reoperations (3.9%), including 2 patients with pseudarthroses (1.1%), one of which manifested after a high-energy trauma.
CONCLUSIONS: A commercially available calcium phosphate and hydroxyapatite bone graft substitute, used in conjunction with locally obtained autograft, safely achieved fusion in 98.9% of patients with JIS or AIS.
METHODS: We retrospectively identified patients with JIS or AIS who underwent PSF using a synthetic bone graft substitute (Mastergraft™; Medtronic, Minneapolis, MN, USA) at Akron Children's Hospital between 2015 and 2022. Patients with <23 months clinical and radiographic follow-up were excluded. Patient demographics, deformity metrics, and surgical data were collected. The primary outcome measure was fusion. Secondary outcome measures included intra-operative and post-operative complications, revision surgeries, and readmissions within 30 and 90 days.
RESULTS: A total of 179 patients were included (mean age, 14.7 years; 72.1% female). A total of 60 cc of synthetic bone graft substitute was used in the majority (91.6%) of cases. At mean 40.9 months (range, 23-98 months) follow-up, 98.9% of patients successfully achieved fusion. There were 7 reoperations (3.9%), including 2 patients with pseudarthroses (1.1%), one of which manifested after a high-energy trauma.
CONCLUSIONS: A commercially available calcium phosphate and hydroxyapatite bone graft substitute, used in conjunction with locally obtained autograft, safely achieved fusion in 98.9% of patients with JIS or AIS.